Evidence map›Paper›PMID 29314658›Full record

ArticleJournal of the International AIDS Society2018

Comparative assessment of five trials of universal HIV testing and treatment in sub-Saharan Africa.

Delphine Perriat, Laura Balzer, Richard Hayes, Shahin Lockman, Fiona Walsh, Helen Ayles, Sian Floyd, Diane Havlir, Moses Kamya, Refeletswe Lebelonyane and 9 more

Registry-linked trialAbstract readComparative Study
In one paragraph

Article in Journal of the International AIDS Society, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01965470 (Botswana Combination Prevention Project), which is not on this map. Cited by 62 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01965470 phase4completednot on this map

Botswana Combination Prevention Project: -Evaluation Protocol (Protocol #1): Research Design and Impact Evaluation -Closed Clinical Cohort Protocol (Protocol #3) Implementation, Monitoring and Evaluation of Combination HIV Prevention Interventions in Rural and Peri-Urban Communities in Botswana

TypeinterventionalSponsorCenters for Disease Control and PreventionRan2013 to 2018ConditionsHIVArmsCombination Prevention, Enhanced Care
3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Article
  14. Article
  15. Article
  16. Article
  17. Observational
  18. Article
  19. Observational
  20. Article

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Delphine PerriatInserm, Bordeaux Population Health Research Center, UMR 1219, University Bordeaux, Bordeaux, France.ORCID 0000-0001-7498-1700
Laura BalzerUniversity of California San Francisco, San Francisco, CA, USA (SEARCH trial).ORCID 0000-0002-3730-410X
Richard HayesDepartment of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom (PopART trial).
Shahin LockmanHarvard School of Public Health, Boston, MA, USA (BCPP trial).
Fiona WalshClinton Health Access Initiative, Boston, MA, USA (MaxART trial).
Helen AylesDepartment of Clinical Research, London School of Hygiene & Tropical Medicine, London, United Kingdom (PopART trial).
Sian FloydDepartment of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom (PopART trial).
Diane HavlirUniversity of California San Francisco, San Francisco, CA, USA (SEARCH trial).
Moses KamyaMakerere University School of Medicine, Uganda (SEARCH trial).
Refeletswe LebelonyaneMinistry of Health, Republic of Botswana, Gaborone, Botswana (BCPP).
Lisa A MillsCenters for Disease Control, Gaborone, Botswana (BCPP trial).
Velephi OkelloMinistry of Health, Kingdom of Swaziland, Mbabane, Swaziland (MaxART trial).
Maya PetersenUniversity of California Berkeley School of Public Health, Berkeley, CA, USA (SEARCH trial).
Deenan PillayAfrica Health Research Institute, Somkhele, KwaZulu-Natal, South Africa (ANRS TasP trial).
Kalpana SabapathyDepartment of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom (PopART trial).ORCID 0000-0001-8017-6716
Kathleen WirthDepartment of Infection, University College London, London, United Kingdom (ANRS TasP trial).
Joanna Orne-GliemannInserm, Bordeaux Population Health Research Center, UMR 1219, University Bordeaux, Bordeaux, France.
François DabisInserm, Bordeaux Population Health Research Center, UMR 1219, University Bordeaux, Bordeaux, France.ORCID 0000-0002-1614-8857
Universal Test and Treat Trials Consortium (UT3C)

Funding

Reducing Failure-to-Initiate ART: Streamlined ART Start Strategy (START)U01AI099959 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HAVLIR, DIANE V · 2012 to 2016
$39.7M
CGH CDC HHS U01 GH000447CGH CDC HHS U2G GH001911Medical Research Council MR/K012126/1NIAID NIH HHS U01 AI099959
6 · The paper itself

Abstract

designUniversal voluntary HIV counselling and testing followed by prompt initiation of antiretroviral therapy (ART) for all those diagnosed HIV-infected (universal test and treat, UTT) is now a global health standard. However, its population-level impact, feasibility and cost remain unknown. Five community-based trials have been implemented in sub-Saharan Africa to measure the effects of various UTT strategies at population level: BCPP/YaTsie in Botswana, MaxART in Swaziland, HPTN 071 (PopART) in South Africa and Zambia, SEARCH in Uganda and Kenya and ANRS 12249 TasP in South Africa. This report describes and contrasts the contexts, research methodologies, intervention packages, themes explored, evolution of study designs and interventions related to each of these five UTT trials.

methodsWe conducted a comparative assessment of the five trials using data extracted from study protocols and collected during baseline studies, with additional input from study investigators. We organized differences and commonalities across the trials in five categories: trial contexts, research designs, intervention packages, trial themes and adaptations.

resultsAll performed in the context of generalized HIV epidemics, the trials highly differ in their social, demographic, economic, political and health systems settings. They share the common aim of assessing the impact of UTT on the HIV epidemic but differ in methodological aspects such as study design and eligibility criteria for trial populations. In addition to universal ART initiation, the trials deliver a wide range of biomedical, behavioural and structural interventions as part of their UTT strategies. The five studies explore common issues, including the uptake rates of the trial services and individual health outcomes. All trials have adapted since their initiation to the evolving political, economic and public health contexts, including adopting the successive national recommendations for ART initiation.

conclusionsWe found substantial commonalities but also differences between the five UTT trials in their design, conduct and multidisciplinary outputs. As empirical literature on how UTT may improve efficiency and quality of HIV care at population level is still scarce, this article provides a foundation for more collaborative research on UTT and supports evidence-based decision making for HIV care in country and internationally.

Indexed as

AdultAfrica South of the SaharaClinical Trials as TopicEpidemicsFemaleHIV InfectionsHumansMaleResearch Designcomparative assessmentHIVprotocolsrandomized trialssub-Saharan Africauniversal test and treat

Identifiers

PMID29314658
PMCPMC5810333

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.